Pharmacological treatment of depression in women with breast cancer: a systematic review
- 778 Downloads
The objective of this study is to review the literature on pharmacological treatment of depression in women with breast cancer. According to the PRISMA guidelines, we conducted a systematic review of randomized, controlled clinical trials and open label prospective studies on antidepressants effects on depression in women with breast cancer up to January 14, 2013. In this analysis, a total of 213 studies were identified, and six studies met the inclusion criteria. Of the six studies, three were placebo-controlled randomized controlled clinical trials with fluoxetine, a selective serotonin reuptake inhibitor; and Mianserin—a noradrenergic and specific serotonergic antidepressant. Both studies found that fluoxetine and mianserin significantly improved depressive symptoms and quality of life (QOL) compared with placebo. Conversely, desipramine, a tricyclic antidepressant, and the SSRI, paroxetine, showed no significant effects on depression compared with placebo. A double-blind, parallel group study comparing a tricyclic antidepressant, amitriptyline, and paroxetine showed a significant and comparable improvement in depression and QOL. Two open label, prospective studies found that escitalopram and the norepinephrine reuptake inhibitor, reboxetine, significantly improved depression and QOL compared with baseline values. In conclusion, depression is a clinical problem in patients with breast cancer. Pharmacological treatment with antidepressants may improve depression and QOL. However, the evidence is limited, and the studies are too heterogeneous to recommend one regimen or drug over another. Further antidepressant studies are needed to guide depression treatment in patients with breast cancer.
KeywordsBreast cancer Oncology Antidepressants Depression Depressive symptoms Pharmacological treatment
The Lundbeck foundation supported the main author Lærke Toftegård Andersen with a scholarship.
Conflict of interest
The authors declare that they have no commercial or other associations that might pose a conflict of interest in connection with this article.
- 5.Mitchell AJ, Chan M, Bhatti H, Halton M, Grassi L, Johansen C, Meader N (2011) Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol 12:160–174. doi: 10.1016/S1470-2045(11)70002-X PubMedCrossRefGoogle Scholar
- 6.Dalton SO, Laursen TM, Ross L, Mortensen PB, Johansen C (2009) Risk for hospitalization with depression after a cancer diagnosis: a nationwide, population-based study of cancer patients in Denmark from 1973 to 2003. J Clin Oncol 27:1440–1445. doi: 10.1200/JCO.2008.20.5526 PubMedCrossRefGoogle Scholar
- 13.Rosso S, Gondos A, Zanetti R, Bray F, Zakelj M, Zagar T, Smailyte G, Ponti A, Brewster DH (2010) Up-to-date estimates of breast cancer survival for the years 2000–2004 in 11 European countries: the role of screening and a comparison with data from the United States. Eur J Cancer 46:3351–3357. doi: 10.1016/j.ejca.2010.09.019 PubMedCrossRefGoogle Scholar
- 21.Meade E, Dowling M (2012) Early breast cancer: diagnosis, treatment and survivorship. Br J Nurs 21:S4–8, S10Google Scholar
- 24.Musselman DL, Somerset WI, Guo Y, Manatunga AK, Porter M, Penna S, Lewison B, Goodkin R, Lawson K, Lawson D, Evans DL, Nemeroff CB (2006) A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. J Clin Psychiatry 67:288–296PubMedCrossRefGoogle Scholar
- 27.Park HY, Lee B-J, Kim J-H, Bae J-N, Hahm B-J (2012) Rapid improvement of depression and quality of life with escitalopram treatment in outpatients with breast cancer: a 12-week, open-label prospective trial. Prog Neuropsychopharmacol Biol Psychiatry 36:318–323. doi: 0.1016/j.pnpbp.2011.11.010 PubMedCrossRefGoogle Scholar
- 36.Siegelmann-Danieli N, Kurnik D, Lomnicky Y, Vesterman-Landes J, Katzir I, Biallik M, Loebstein R (2011) Potent CYP2D6 inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen. Breast Cancer Res Treat 125:505–510. doi: 10.1007/s10549-010-1008-7 PubMedCrossRefGoogle Scholar
- 46.Lengacher CA, Johnson-Mallard V, Post-White J, Moscoso MS, Jacobsen PB, Klein TW, Widen RH, Fitzgerald SG, Shelton MM, Barta M, Goodman M, Cox CE, Kip KE (2009) Randomized controlled trial of mindfulness-based stress reduction (MBSR) for survivors of breast cancer. Psychooncology 18:1261–1272. doi: 10.1002/pon.1529 PubMedCrossRefGoogle Scholar
- 47.Henderson VP, Clemow L, Massion AO, Hurley TG, Druker S, Hébert JR (2012) The effects of mindfulness-based stress reduction on psychosocial outcomes and quality of life in early-stage breast cancer patients: a randomized trial. Breast Cancer Res Treat 131:99–109. doi: 10.1007/s10549-011-1738-1 PubMedCrossRefGoogle Scholar
- 48.Würtzen H, Dalton SO, Elsass P, Sumbundu AD, Steding-Jensen M, Karlsen RV, Andersen KK, Flyger HL, Pedersen AE, Johansen C (2013) Mindfulness significantly reduces self-reported levels of anxiety and depression: results of a randomised controlled trial among 336 Danish women treated for stage I–III breast cancer. Eur J Cancer 49:1365–1373. doi: 10.1016/j.ejca.2012.10.030 PubMedCrossRefGoogle Scholar
- 49.Hoffman CJ, Ersser SJ, Hopkinson JB, Nicholla PG, Harrington JE, Thomas PW (2012) Effectiveness of mindfulness-based stress reduction in mood, breast- and endocrine-related quality of life, and well-being in stage 0 to III breast cancer: a randomized, controlled trial. J Clin Oncol 30:1335–1342. doi: 10.1200/JCO.2010.34.033.1 PubMedCrossRefGoogle Scholar